OncoMatch/Clinical Trials/NCT04973605
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Is NCT04973605 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for relapsed/refractory multiple myeloma.
Treatment: Sonrotoclax · Dexamethasone · Carfilzomib · Daratumumab · Pomalidomide — The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14). The study investigates sonrotoclax alone and in combination with dexamethasone and other agents, including carfilzomib, daratumumab, and pomalidomide.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: CCND1 t(11;14) translocation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody
Must have received: IMiD
had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody
Must have received: anti-CD38 monoclonal antibody
had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody
Cannot have received: BCL2 inhibitor (sonrotoclax, venetoclax)
Prior therapy with sonrotoclax or other agents inhibiting BCL2 activity (eg, venetoclax)
Lab requirements
Blood counts
Hemoglobin ≥ 8.0 g/dL (transfusions permitted); Platelet count ≥ 75,000/μL independent of growth factor support and transfusions; ANC ≥ 1000/mm^3
Liver function
ALT and AST ≤ 3 x ULN and total bilirubin ≤ 2.0 x ULN (total bilirubin must be < 3 x ULN for patients with Gilbert's syndrome)
Adequate organ function defined as: Hemoglobin ≥ 8.0 g/dL within 7 days before first dose of study treatment, (transfusions, in accordance with institutional guidelines, are permitted); Platelet count ≥ 75,000/μL, within 7 days before first dose of study treatment, independent of growth factor support and transfusions; Absolute neutrophil count (ANC) ≥ 1000/mm^3 within 7 days before first dose of study treatment; ALT and AST ≤ 3 x ULN and total bilirubin ≤ 2.0 x ULN (total bilirubin must be < 3 x ULN for patients with Gilbert's syndrome)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama At Birmingham Hospital · Birmingham, Alabama
- City of Hope National Medical Center · Duarte, California
- City of Hope Irvine Lennar · Irvine, California
- University of California At San Francisco · San Francisco, California
- University of Miami · Miami, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04973605 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BCL2 inhibitor disqualifies patients from enrollment.
Does this trial require CCND1?
Yes, CCND1 t(11;14) translocation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages